TRDA
HEALTHCAREEntrada Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving TRDA Today?
No stock-specific AI insight has been generated for TRDA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$16.03
Fundamentals
Trading
TRDA News
20 articles- Entrada’s stock drops as DMD drug’s efficacy falls shortClinicaltrialsarena·May 8, 2026
- Sarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?Yahoo Finance·May 7, 2026
- Sector Update: Health Care Stocks Softer Late AfternoonYahoo Finance·May 7, 2026
- Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 7, 2026
- Entrada shares dive as Duchenne results disappointBiopharmadive·May 7, 2026
- Entrada Therapeutics Reports First Quarter 2026 Financial ResultsYahoo Finance·May 7, 2026
- Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 StudyYahoo Finance·May 7, 2026
- Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026Yahoo Finance·May 6, 2026
- Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?Yahoo Finance·May 5, 2026
- Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 4, 2026
- Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million ExitMotley Fool·Mar 18, 2026
- Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million ExitMotley Fool·Mar 18, 2026
- Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Mar 2, 2026
- Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Feb 26, 2026
- Arcutis Biotherapeutics, Inc. (ARQT) Surpasses Q4 Earnings and Revenue EstimatesYahoo Finance·Feb 26, 2026
- Repligen (RGEN) Tops Q4 Earnings and Revenue EstimatesYahoo Finance·Feb 24, 2026
- Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to DeclineYahoo Finance·Feb 19, 2026
- EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains?Yahoo Finance·Feb 18, 2026
- Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 StudyYahoo Finance·Feb 17, 2026
- Entrada Therapeutics Teases Data-Rich 2026 With DMD and DM1 Catalysts at Guggenheim SummitMarketbeat·Feb 15, 2026
All 20 articles loaded
Price Data
52-Week Range
$16.03
Fundamentals
Trading
About Entrada Therapeutics Inc
Entrada Therapeutics Inc. (TRDA) is an innovative biotechnology company dedicated to developing groundbreaking therapies to address severe diseases with significant unmet medical needs. Utilizing its proprietary Therapeutics for RNA Delivery (TRADA) platform, Entrada targets RNA and protein dysfunctions linked to conditions such as muscular dystrophies and genetic disorders. The firm boasts a strong clinical pipeline and a commitment to scientific excellence, positioning itself well for impactful advancements in patient care. Led by an experienced team, Entrada is poised to make significant contributions to the biopharmaceutical industry through its cutting-edge therapeutic solutions.